戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eal cancer among the women who had undergone prophylactic surgery.
2 nography examinations within 6 months before prophylactic surgery.
3 esults tended to reinforce intentions toward prophylactic surgery.
4  only if all women who test positive undergo prophylactic surgery.
5 ocumented the occurrence of cancer following prophylactic surgery.
6  mm appears to be a reasonable threshold for prophylactic surgery.
7 ront modern combination chemotherapy without prophylactic surgery.
8         Among unaffected women with no prior prophylactic surgery, 17% of carriers (2/12) intended to
9 e who completed testing surveyed interest in prophylactic surgery after counseling and receiving test
10                      Additionally, elective 'prophylactic' surgery after diverticulitis, previously c
11 ectomy and prophylactic oophorectomy with no prophylactic surgery among women who carry mutations in
12 RCA2 (BRCA1/2) mutations must choose between prophylactic surgeries and screening to manage their hig
13 ion in cancer incidence and mortality due to prophylactic surgeries and/or tamoxifen were estimated f
14 e expectancy decline with age at the time of prophylactic surgery and are minimal for 60-year-old wom
15 h BRCA1/2 mutations in their choices between prophylactic surgery and breast screening.
16 ement of this cancer syndrome currently uses prophylactic surgery and enhanced cancer surveillance st
17      The individual patient's choice between prophylactic surgery and surveillance is a complex decis
18 ondary cancer prevention strategies, such as prophylactic surgery and tamoxifen therapy.
19                      Women who had undergone prophylactic surgery and their matched controls were fol
20 finding cancer in these women at the time of prophylactic surgery, and careful pathologic assessment
21 ailable to them, including watchful waiting, prophylactic surgery, and chemoprevention.
22 ective estrogen receptor modulators (SERMs), prophylactic surgery, and lifestyle change.
23 inical and genetic indications and timing of prophylactic surgery, and the efficacy of prophylactic s
24 eling providers predicted they would opt for prophylactic surgery at a young age if they carried a BR
25 positive for a BRCA1 or BRCA2 gene mutation, prophylactic surgery at a young age substantially improv
26 dy updates findings regarding the effects of prophylactic surgery, chemoprevention, and surveillance
27 of AAs that enlarged led to clinical events (prophylactic surgery, dissection, or rupture).
28                    Eleven patients completed prophylactic surgery due to a high risk for breast cance
29     No recommendation is made for or against prophylactic surgery (eg, mastectomy, oophorectomy); the
30 nd angiotensin-converting enzyme inhibitors; prophylactic surgery for aneurysm; surgical techniques f
31 reviewed from BRCA-positive women undergoing prophylactic surgery for ovarian cancer risk reduction w
32 etic testing, colonoscopic surveillance, and prophylactic surgery for the relatives of index cases.
33     No recommendation is made for or against prophylactic surgery (ie, colectomy, hysterectomy); thes
34 urgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are
35 rt current consensus guidelines recommending prophylactic surgery in nonsyndromic individuals with TA
36 y 2007, 122 BRCA-positive patients underwent prophylactic surgery in the Division of Gynecologic Onco
37                                              Prophylactic surgery is cost-effective for years of life
38                                              Prophylactic surgery is generally not recommended for av
39 ; options to reduce cancer mortality include prophylactic surgery or breast screening, but their effi
40 n carriers, decision analysis indicates that prophylactic surgery or chemoprevention leads to better
41 an previously reported from chemoprevention, prophylactic surgery, or a combination.
42 idence of cancer, prognosis, and efficacy of prophylactic surgery, our model suggests that prophylact
43 ng depression, functional health status, and prophylactic surgery plans [follow-up only]) were assess
44 ence near equal probability of dissection vs prophylactic surgery, possibly because of failure of ear
45  referral of selected high-risk patients for prophylactic surgery prevents development of CRC in SPS
46                     Observational studies of prophylactic surgeries report reduced risks for breast a
47 nt colorectal cancer begun in the 1960s) and prophylactic surgeries, such as in Lynch syndrome patien
48 nt rates of germline testing, screening, and prophylactic surgery, the strategies reduced deaths from
49 rated the ability of molecular diagnosis and prophylactic surgery to improve patient outcomes.
50 participation in chemoprevention trials, and prophylactic surgery to remove at-risk tissues.
51                                              Prophylactic surgeries were cost-effective compared with
52 ed risks for breast and ovarian cancer after prophylactic surgeries were obtained from the literature
53 of prophylactic surgery, and the efficacy of prophylactic surgery when known.